Akoya Biosciences, Inc. (AKYA)
| Market Cap | 819.78M |
| Revenue (ttm) | 42.44M |
| Net Income (ttm) | -16.71M |
| Shares Out | 35.69M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $22.97 |
| Previous Close | $26.05 |
| Change ($) | -3.08 |
| Change (%) | -11.82% |
| Day's Open | 24.60 |
| Day's Range | 22.60 - 25.23 |
| Day's Volume | 578,316 |
| 52-Week Range | 22.60 - 28.96 |
MARLBOROUGH, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its initial public offering of 6,580...
Akoya Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
About AKYA
Akoya Biosciences is an innovative life sciences technology company whose mission is to deliver a revolutionary new class of spatially derived biomarkers that empower life sciences researchers to better understand disease and clinicians to improve patient outcomes. Spatial biology refers to a rapidly evolving technology that enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single cell resolution, enabling advancements in their understanding of disease progre... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Apr 16, 2021 |
| CEO Brian McKelligon | Employees 169 |
| Stock Exchange NASDAQ | Ticker Symbol AKYA |
Financial Performance
In 2020, AKYA's revenue was $42.44 million, an increase of 0.49% compared to the previous year's $42.24 million. Losses were -$16.71 million, 13.3% more than in 2019.